Tecovirimat Powder Cas No.869572-92-9

Tecovirimat Powder Cas No.869572-92-9

Product Name: Tecovirimat Powder
Product Source: Synthetic
Product Specification: ≥98%
CAS No.: 869572-92-9
Molecular Formula: C₁₉H₁₅F₃N₂O₃
Molecular Weight: 376.33 g/mol
Test Method: HPLC
Active Ingredient: Tecovirimat
Product Characteristics: White to off-white powder
Product Packaging: 1kg/bag; 25kg/drum
Storage Conditions: Store in light-protected, inert atmosphere at room temperature
Shelf Life: 24 months

Declaration of Use: This product is intended for industrial use or scientific research only.
Send Inquiry

What is Tecovirimat API?

Tecovirimat API Powder CAS 869572-92-9

High-Purity Tecovirimat API Powder | CAS 869572-92-9

Tecovirimat (CAS No. 869572-92-9), also known as ST-246, is a potent, narrow-spectrum antiviral Active Pharmaceutical Ingredient (API) specifically developed for the treatment of orthopoxvirus infections, including Mpox (monkeypox), smallpox, and cowpox. Manufactured under stringent cGMP-compliant protocols at Xi'an Tihealth, our Tecovirimat powder achieves an HPLC-validated purity of ≥98.0%. Unlike nucleoside analogues that inhibit DNA synthesis, Tecovirimat functions as a highly selective viral egress inhibitor. This pharmaceutical-grade API is optimized for the industrial formulation of oral capsules and parenteral solutions, ensuring robust crystalline stability and reliable pharmacokinetic performance for critical public health countermeasures.

Technical Specifications & TDS

Parameter Product Specification
Chemical Name N-[(3aR,4R,4aS,5aS,6S,6aS)-2,2,6-trioxo-4-(trifluoromethyl)-4,4a,5,5a,6,6a-hexahydro-3aH-4,6-ethenocyclopropa[f]isoindol-2-yl]benzamide
CAS Number 869572-92-9
Molecular Formula C19​H15​F3​N2​O3​
Molecular Weight 376.33 g/mol
Assay (HPLC) ≥ 98.0%
Appearance White to off-white crystalline powder
Storage Conditions Light-protected, under inert atmosphere (RT)

What is the Mechanism of Action?

Tecovirimat exerts its antiviral activity through a unique targeted mechanism that prevents viral dissemination:

  • VP37 Protein Inhibition: Tecovirimat specifically targets the orthopoxvirus VP37 envelope wrapping protein (encoded by the F13L gene). By binding to VP37, it disrupts the interaction between the viral particle and the host cell's transport machinery.
  •  
  • Blockade of Viral Egress: This interaction prevents the formation of Extracellular Enveloped Virus (EEV), the form of the virus responsible for cell-to-cell spread and long-range systemic dissemination within the host.
  •  
  • Containment of Infection: By arresting the egress phase of the viral life cycle, Tecovirimat effectively contains the infection to the initial site, allowing the host's immune system to clear the non-disseminated intracellular mature virions (IMV).

Pharmaceutical Formulation Applications

  • Oral Capsule Manufacturing: The primary API utilized for developing 200 mg solid oral dosage forms prescribed for acute orthopoxvirus management.
  •  
  • Pediatric Liquid Formulations: Suitable for development into taste-masked suspensions for pediatric emergency use.
  •  
  • Antiviral R&D: Essential starting material for investigating resistance pathways in poxvirus and developing high-efficacy therapeutic regimens.

Strict Compliance Notice: Intended for industrial manufacturing and scientific research only. Not for individual clinical use. Storage must be maintained under an inert atmosphere and protected from light to prevent potential oxidative degradation.

Frequently Asked Questions (FAQ)

What makes Tecovirimat unique compared to Brincidofovir?

While Brincidofovir inhibits viral DNA polymerase, Tecovirimat is the first antiviral to specifically inhibit the viral egress protein VP37. This unique MOA makes it a critical part of dual-therapy protocols and a first-line countermeasure against orthopoxvirus outbreaks due to its oral bioavailability and targeted action.

 

How does Xi'an Tihealth ensure the stability of Tecovirimat API?

We maintain a rigorous quality management system that includes multi-stage crystallization and final vacuum packaging under Argon or Nitrogen. Every batch is validated via HPLC to ensure purity exceeds 98.0%, maintaining potency throughout its 24-month shelf life when stored correctly.

 
 
 
 
 
 
 
 

Hot Tags: tecovirimat powder cas no.869572-92-9, China tecovirimat powder cas no.869572-92-9 manufacturers, suppliers, factory, hialuronato de sodio hialuronato sodico sodium hyaluronate, , ,

Send Inquiry